glp-1 for mash receptor agonists improve mostly via extrahepatic actions: 1️⃣ CNS appetite control → weight loss → ↓ systemic inflammation 2️⃣ ↓ Chylomicron synthesis & improve lipid metabolism 3️⃣ Bind… Novo Nordisk leads MASH therapeutic
Description
This product is not intended to replace professional medical advice, diagnosis, or treatment
In the field of weight loss drug development, the recently disclosed clinical data of Amgens weight loss candidate drug Maridebart Cafraglutide (referred to as MariTide, formerly known as AMG 133) has drawn widespread attention in the industry and is considered a potential Game Changer. The reason why MariTide is seen as a game-changer in the weight loss drug market dominated by Wegovy and Zepbound is an important factor: MariTides molecular modality is a unique antibody-peptide conjugate (also known as Peptibody)
2021;106:e1738e1754
By joining Cureus, you agree to our Privacy Policy and Terms of Use.
Learning to eat to the point of satisfaction rather than fullness is an important behavioral adjustment
What Is Foundayo (Orforglipron)
